

ASX ANNOUNCEMENT

28 November 2022

Anteris DurAVR™ THV presented at the TAVI: Late Breaking Trials and Innovations session at Major International Meeting - PCR London Valves

LONDON, UK and BRISBANE, Australia, Anteris Technologies Ltd (**Anteris** or the **Company**) (ASX: AVR), announced today the presentation of “DurAVR™ transcatheter aortic valve first-in-human study: impact of novel leaflet design” at the annual PCR London Valves 2022, 27-29 November 2022.

Anteris was honoured to accept an opportunity from the PCR Conference Scientific Committee to present at the TAVI: Late-Breaking Trials and Innovations session. The conference was attended by more than 3,000 participants from over 100 countries.

Dr Chris Meduri, MD, Anteris Chief Medical Officer and Interventional Cardiologist, Karolinska University Hospital, Stockholm, presented results from the DurAVR™ transcatheter aortic valve first-in-human study, providing preliminary echo, CT, and MRI evidence of improved haemodynamic and laminar flow characteristics associated with the DurAVR™ Transcatheter Heart Valve (THV) System.

This prospective, non-randomised, single-arm, single-centre study to evaluate the safety and feasibility of DurAVR™ THV was conducted in a patient cohort of 13 subjects with severe symptomatic aortic stenosis including challenging anatomies such as Type 1 bicuspid and extreme leaflet calcium.

Post-procedural outcomes from the study demonstrated:

- Mean annulus diameter 22.3 ± 1.07 mm
- Mean valve leaflet coaptation length of 8.3 mm
- 100% procedural success
- No device-related complications
- No moderate or severe paravalvular leak
- Excellent haemodynamic results at 30 days
- Consistent laminar aortic flow shown at 30 days echo and CT results
- Improved exercise capacity as measured by 6MWT (first 5 subjects only)
- No changes in cardiac electrical conductivity at 6 months (first 5 subjects only)

Dr Chris Meduri said “the DurAVR™ THV FIH study provides encouraging echo, CT, and MRI evidence of improved haemodynamics and laminar flow characteristics associated with the single-piece, native-shaped leaflet design. It is producing excellent haemodynamic results at 30 days with consistent laminar aortic flow throughout the valve structure”

Anteris CEO Wayne Paterson said “DurAVR™ THV is designed with shaping technology to address the major unmet patient need for superior haemodynamic performance and long-term durability. We are continuing to work to establish the clinical value of our new and highly differentiated DurAVR™ THV”

ENDS

Anteris Technologies Ltd Registered Office:

Toowong Tower, Suite 302, Level 3, 9 Sherwood Rd, Toowong, Queensland, 4066

Customer Service

T +61 1300 550 310 | F +61 1300 972 437 | E info.au@anteristech.com | W anteristech.com

Brisbane • Minneapolis • Geneva • Malaga



About Anteris Technologies Ltd (ASX: AVR)

Anteris Technologies Ltd is a structural heart company that delivers clinically superior and durable solutions through better science and better design.

Its focus is developing next-generation technologies that help healthcare professionals deliver consistent life-changing outcomes for patients.

Anteris' DurAVR™ single-piece, native-shaped aortic heart valve replacement addresses the needs of today's younger and more active aortic stenosis patients by delivering superior performance and durability through innovations designed to last the remainder of a patient's lifetime.

The proven benefits of its patented ADAPT® tissue technology, paired with the unique design of our DurAVR™ single-piece, native-shaped aortic heart valve, have the potential to deliver a game-changing treatment to aortic stenosis patients worldwide and provide a much-needed solution to the challenges facing doctors today.

Authorisation and Additional information

This announcement was authorised by the Board of Directors.

For more information:

Investor contact

Deanne Curry
GRACosway
E: investors@anteristech.com
M: +61 414 388 997

Media contact

Nick Howe
GRACosway
nhowe@gracosway.com.au
M: +61 407 183 221

www.anteristech.com
Twitter: @AnterisTech
Facebook: www.facebook.com/AnterisTech
LinkedIn: <https://www.linkedin.com/company/anteristech>